Davalagi Shubha B, Nayak Vaman P, Ghose Anisha, Marakatti Siddarth S, Kasturi Eshwar S, Maganahalli Anurupa S
Department of Community Medicine, JJM Medical College, Davangere, Karnataka, India.
J Family Med Prim Care. 2023 Nov;12(11):2869-2874. doi: 10.4103/jfmpc.jfmpc_176_23. Epub 2023 Nov 21.
India has launched COVID vaccination program on January 16, 2021 and precautionary dose (third dose) on January 10, 2022. Our study evaluated adverse events following immunization (AEFI) among healthcare workers (HCWs) following first, second, and precautionary dose of ChAdOx1 nCoV-19 (COVISHIELD) vaccine. We also evaluated the association of AEFI with the study participants' characteristics.
(1) To assess the adverse events among HCWs following first, second, and precautionary dose of COVISHIELD vaccine. (2) To determine the factors associated with adverse events of COVISHIELD vaccine.
A retrospective cohort study was conducted among HCWs of a tertiary care teaching hospital in central Karnataka from January 2021 to June 2022. A semi-structured, pretested questionnaire was used to interview the HCW of tertiary care teaching hospital regarding adverse events following first, second, and precautionary dose of COVISHIELD vaccine; data collected was entered in MS Excel 2019 and analyzed using SPSS v24.0.
Among 454 participants majority of them were females (231, 50.88%) and in the age group 18-27 years (151, 33.25%), and the majority were nursing staff (147, 32.37%). Adverse events were reported among 204 (44.93%) following the first dose, 149 (32.81%) after the second dose, and 230 (50.66%) participants following the precautionary dose. Generalized weakness and fever were the common adverse effects reported by participants.
Majority of the study population did not report any adverse events following vaccination. Among the study participants who reported adverse events, most events were reported on the same day. Symptoms were mild in severity and short-lived.
印度于2021年1月16日启动了新冠疫苗接种计划，并于2022年1月10日开始接种加强针（第三剂）。我们的研究评估了医护人员在接种第一剂、第二剂和加强针ChAdOx1 nCoV-19（COVISHIELD）疫苗后的免疫接种后不良事件（AEFI）。我们还评估了AEFI与研究参与者特征之间的关联。
（1）评估医护人员在接种第一剂、第二剂和加强针COVISHIELD疫苗后的不良事件。（2）确定与COVISHIELD疫苗不良事件相关的因素。
2021年1月至2022年6月，在卡纳塔克邦中部一家三级护理教学医院的医护人员中进行了一项回顾性队列研究。使用一份经过预测试的半结构化问卷，就接种第一剂、第二剂和加强针COVISHIELD疫苗后的不良事件对三级护理教学医院的医护人员进行访谈；收集到的数据录入MS Excel 2019，并使用SPSS v24.0进行分析。
在454名参与者中，大多数为女性（231名，50.88%），年龄在18 - 27岁之间（151名，33.25%），且大多数为护理人员（147名，32.37%）。第一剂接种后有204名（44.93%）报告了不良事件，第二剂接种后有149名（32.81%），加强针接种后有230名（50.66%）参与者报告了不良事件。参与者报告的常见不良反应为全身无力和发热。
大多数研究人群在接种疫苗后未报告任何不良事件。在报告了不良事件的研究参与者中，大多数事件发生在同一天。症状严重程度较轻且持续时间较短。
